{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:06:29Z","timestamp":1790003189123,"version":"4.0.1"},"reference-count":8,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2022,10,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-508","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T22:09:18Z","timestamp":1653862158000},"page":"494-499","source":"Crossref","is-referenced-by-count":2,"title":["Prevention of New Metastatic Lesions by Eribulin Monotherapy Is Associated with Better Prognosis in Patients with Metastatic Breast Cancer"],"prefix":"10.1272","volume":"89","author":[{"given":"Yukiko","family":"Hara","sequence":"first","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014 Mar 18;110 (6):1497-505.","DOI":"10.1038\/bjc.2014.80"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kashiwagi S, Asano Y, Goto W, et al. Mesenchymal-epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer. Anticancer Res. 2018 Jan 1;38 (1):401-10.","DOI":"10.21873\/anticanres.12236"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: Mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015 Jun 1;21 (11):2445-52.","DOI":"10.1158\/1078-0432.CCR-14-3252"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cortes J, Sch\u00f6ffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treat Rev. 2018 Nov 1;70:190-8.","DOI":"10.1016\/j.ctrv.2018.08.008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. O'Shaughnessy J, Kaklamani V, Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019 May;15 (14):1641-53.","DOI":"10.2217\/fon-2018-0936"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet. 2011 Mar 12;377 (9769):914-23.","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mori R, Futamura M, Morimitsu K, et al. The mode of progressive disease affects the prognosis of patients with metastatic breast cancer. World J Surg Oncol. 2018 Dec;16 (1):169.","DOI":"10.1186\/s12957-018-1472-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fujii T, Tokuda S, Nakazawa Y, et al. Eribulin suppresses new metastases in patients with metastatic breast cancer. In Vivo. 2020 Mar-Apr;34 (2):917-21.","DOI":"10.21873\/invivo.11858"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/5\/89_JNMS.2022_89-508\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T04:58:03Z","timestamp":1668229083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/5\/89_JNMS.2022_89-508\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-508","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"article-number":"JNMS.2022_89-508"}}